TABLE 1

Clinical and pathological baseline characteristics (all patients)

Subjects303
Age at nivolumab initiation years65 (17–91)
Sex
 Male208 (69)
 Female95 (31)
Smoking history
 Never-smoker23 (8)
 Current or ex-smoker278 (92)
 Missing data2 (1)
Histology on initial biopsy
 Adenocarcinoma186 (61)
 Squamous cell carcinoma86 (28)
 Giant cell carcinoma20 (7)
 Sarcomatoid carcinoma4 (1)
 Adenosquamous carcinoma3 (1)
 Muco-epidermoid carcinoma2 (1)
 Undifferentiated EBV-linked carcinoma1 (<1)
 Missing1 (<1)
Mutational status
 EGFR10 (3)
 KRAS50 (17)
 ALK2 (1)
 BRAF7 (2)
 Wild-type219 (72)
 Other15 (5)
Stage at diagnosis
 Stage I–II30 (10)
  Post-operative recurrence26 (87)
 Stage III–IV273 (90)
Lines of therapy before nivolumab2 (0–9)
 01 (<1)
 1120 (40)
 288 (29)
 ≥394 (31)
Performance status at nivolumab initiation
 059 (19)
 1145 (48)
 260 (20)
 37 (2)
 42 (1)
 Missing30 (10)
Metastatic sites at nivolumab initiation
 Lung120 (40)
 Pleura88 (29)
 CNS62 (20)
 Liver48 (16)
 Adrenal glands54 (18)
 Bone78 (26)
PD-L1 status determined by IHC120 (40)
 Positive (>1%)31 (10)
 Negative32 (11)
 Not performed240 (79)

Data are presented as n, median (range) or n (%). EBV: Epstein–Barr virus; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; CNS: central nervous system; PD-L: programmed death ligand; IHC: immunohistochemistry.